Pharmaceutical giants are making a big splash in the industry, with a major player announcing its largest deal in over five years. The blockbuster acquisition is the latest in a wave of mergers and acquisitions sweeping the sector, as companies look to bolster their portfolios and stay ahead in a rapidly evolving market. With the pharmaceutical industry facing increasing pressure to deliver innovative treatments and reduce costs, this massive deal is being closely watched by investors and analysts alike, who are eager to see how it will impact the company's future prospects and the wider sector. As the deal is set to shake up the industry landscape, we take a closer look at the implications and what it means for the future of healthcare.
Drugmaker’s largest deal in more than half a decade comes amid surge of M&A in sector
